Quick Answer
Opus Genetics, Inc. reported Cash and Equivalents of $45.09 million for fiscal year 2025.
Opus Genetics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.09M | +48.7% |
| 2024 | $30.32M | -40.0% |
| 2023 | $50.50M | +18.5% |
| 2022 | $42.63M | +73.8% |
| 2021 | $24.53M | +180.6% |
| 2018 | $8.74M | -1.7% |
| 2017 | $8.90M | -23.1% |
| 2016 | $11.58M | +13.5% |
| 2015 | $10.20M | +3.8% |
| 2014 | $9.83M | -47.4% |
| 2013 | $18.69M | +38.6% |
| 2012 | $13.49M | +36.8% |
| 2011 | $9.86M | -20.1% |
| 2010 | $12.34M | +69.1% |
| 2009 | $7.30M | +1877.1% |
| 2008 | $369.1K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.82M | -15.9% | -5.0% |
| June 30, 2025 | $32.43M | -21.7% | -22.4% |
| March 31, 2025 | $41.79M | -11.4% | +37.8% |
| December 31, 2024 | $30.32M | -40.0% | -17.2% |
| September 30, 2024 | $36.63M | -13.5% | -11.5% |
| June 30, 2024 | $41.41M | +3.6% | -12.2% |
| March 31, 2024 | $47.16M | +21.0% | -6.6% |
| December 31, 2023 | $50.50M | +18.5% | +19.2% |
- Opus Genetics, Inc. showed an increase of +48.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Opus Genetics, Inc.’s cash and equivalents has grown by 12115.5% (from $369.1 thousand to $45.09 million).
- The most recent figure is from Opus Genetics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: